We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Biovectra Signs Service Agreement With Acuitas Therapeutics for Unique Lipid Nanoparticle (Lnp) Delivery System Used in Manufacturing mRNA-Based Therapies

A close up of someone holding a glass test tube.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ best-in-class LNP technology platform for manufacturing mRNA-based therapeutics.

“We are thrilled about this partnership with Acuitas Therapeutics, a global leader in LNP delivery systems,” stated Marc Sauer, Ph.D., Chief Science Officer, BIOVECTRA. “Our work together will provide their licensed partners with faster market access to cGMP-quality LNPs for early and late-stage products. BIOVECTRA looks forward to continuing to make a difference in patients’ lives by supporting GMP and commercial-ready LNP formulation at our new mRNA biomanufacturing facility in Atlantic Canada.”

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE
Through this partnership, BIOVECTRA will formulate Acuitas’ LNP for licensed therapeutic partners for clinical and commercial products using a variety of payloads. Acuitas’ proprietary LNP technology is used in multiple vaccines and therapeutics in clinical development and enables COMIRNATY®, the Pfizer-BioNTech COVID-19 vaccine that was first to receive regulatory approval and that has been administered to people in 180 countries.

“LNP-based mRNA medicines provide the opportunity to address an incredibly wide range of health conditions, from infectious diseases such as COVID-19, flu, and malaria to therapeutic areas related to heart disease, or cancer, as well as many rare diseases,” said Dr. Chris Barbosa, Vice President, Technology Development, Acuitas Therapeutics. He added: “As we move forward in the development process in all of these areas with our partners, the demand for Acuitas’ clinical-grade LNP for our partners increases exponentially. We look forward to working with the BIOVECTRA team to expand the cGMP manufacturing capacity for Acuitas’ LNP so that we can continue to meet the growing needs of our global partners.”

The work will occur in BIOVECTRA’s new biomanufacturing centre, which, upon completion later this year, will support the GMP manufacturing of plasmid DNA, mRNA and LNP formulations. This facility adds 36,000 square feet to BIOVECTRA’s existing Charlottetown campus and will be able to produce the equivalent of 160 million doses of mRNA vaccines and to fill/finish 70 million final vaccine doses per year for commercial distribution, providing an end-to-end manufacturing solution for BIOVECTRA’s clients. Currently, BIOVECTRA is fully equipped and staffed with a team of experts at bench scale, to begin the technical transfer of nucleic acid processes that will be destined for manufacture in these new facilities. It also carries a deep track record of GMP commercial supply of lipids (including custom ionizable lipids), complex API’s and drug substances, from its five GMP facilities in Eastern Canada.